Celebrex PRECISION Trial: 'Herculean' Effort, But Missing Information Bugs US FDA Panel
Executive Summary
Pfizer study finds Celebrex's CV risk comparable to naproxen and ibuprofen, but advisory committee wanted data on confounding factors and reasons for high dropout.
You may also be interested in...
Addition Of Celebrex PRECISION Cardiovascular Trial to Label Emphasizes Use Of Lowest Dose
Heeding concerns of an advisory panel, US agency underscores that it is the lowest approved dose of the COX-2 inhibitor that has comparable CV risk to moderate doses of ibuprofen and naproxen.
US FDA Blood Pressure Risk Assessment Guidance Uses Unique Format
As agency embraces bullet-point format, old-school draft full of call-outs and solicitations seems unlike anything before or since. Regardless of style, FDA's testing recommendations for developmental therapies are of broad, substantive interest to industry.
Celebrex Likely To Get Label Change Saying CV Risk Is Comparable To Ibuprofen, Naproxen
Despite concerns about difference in dosages and study discontinuation rates, US FDA advisory committee concludes that Pfizer's study demonstrated similar CV risk among the three NSAIDs.